Bernstein reiterates Market Perform rating on L’Oreal stock, citing strong dermatological division

Bernstein maintained a Market Perform rating on L'Oreal (EPA:OR) with a EUR410.00 price target, citing the company's strong market leadership, 74% gross margins, and an 8% revenue CAGR, significantly bolstered by its dermatological beauty division's 19.5% organic growth from 2018-2024, driven by brands like CeraVe. However, recent analyst sentiment is mixed, with JPMorgan upgrading to Neutral (PT EUR360.00) on an improved U.S. outlook, while Barclays downgraded to Underweight (PT EUR325.00) due to concerns over L'Oreal's declining market outperformance in 2024, reflecting divergent views on its future growth trajectory.

Analysis

L'Oreal SA demonstrates robust financial health, characterized by impressive 74% gross profit margins and a consistent 8% revenue CAGR over the last five years, solidifying its position as a global beauty market leader. The primary engine of recent growth has been its dermatological beauty division, which posted a remarkable 19.5% organic growth rate between 2018 and 2024, far outpacing both the group's average and the broader industry. This surge was predominantly driven by two key brands, CeraVe and La Roche-Posay, which accounted for over 80% of the division's growth, with CeraVe alone expanding its revenue 14-fold since its 2017 acquisition. However, analyst sentiment has become increasingly divergent. While JPMorgan upgraded its rating to Neutral with a EUR360 price target, citing an improved U.S. outlook, Barclays downgraded the stock to Underweight with a EUR325 target. Barclays' bearish stance is rooted in concerns over L'Oreal's declining market outperformance, which fell to 1.1 times in 2024, a notable deceleration from historical averages. This conflict presents a core debate: whether the company's powerful brand-level growth can sustain momentum against signs of a broader slowdown in its relative market dominance.

Key Decisions for Investors

• Investors should weigh L'Oreal's strong fundamentals, particularly the high-growth dermatological division and 74% gross margins, against the emerging risk of decelerating market outperformance as highlighted by Barclays' recent downgrade.
• Monitor upcoming earnings reports for the performance of the dermatological beauty division, as the continued hyper-growth of brands like CeraVe is critical to justifying the company's valuation and offsetting potential weaknesses elsewhere.
• Given the conflicting analyst ratings ranging from Neutral to Underweight, a hold or market-perform-oriented strategy may be prudent until there is clearer evidence of either a re-acceleration in market share gains or a sustained slowdown.
• Pay close attention to management's commentary on the global beauty market outlook for 2025, as their projection of 4% growth is a key assumption underpinning the more optimistic scenarios for the stock.